BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38281029)

  • 1. MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers.
    Liu J; Yang J; Pan Q; Wang X; Wang X; Chen H; Zheng X; Huang Q
    Eur J Med Res; 2024 Jan; 29(1):79. PubMed ID: 38281029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM4 is a rational target for treating breast cancers with mutant p53.
    Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
    J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
    Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.
    Hüllein J; Słabicki M; Rosolowski M; Jethwa A; Habringer S; Tomska K; Kurilov R; Lu J; Scheinost S; Wagener R; Huang Z; Lukas M; Yavorska O; Helfrich H; Scholtysik R; Bonneau K; Tedesco D; Küppers R; Klapper W; Pott C; Stilgenbauer S; Burkhardt B; Löffler M; Trümper LH; Hummel M; Brors B; Zapatka M; Siebert R; Kreuz M; Keller U; Huber W; Zenz T
    Cancer Res; 2019 Jun; 79(12):3125-3138. PubMed ID: 31000522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
    Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
    Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma.
    Wang CL; Wang JY; Liu ZY; Ma XM; Wang XW; Jin H; Zhang XP; Fu D; Hou LJ; Lu YC
    Carcinogenesis; 2014 Jul; 35(7):1500-9. PubMed ID: 24445145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM4 expression in fibrolamellar hepatocellular carcinoma.
    Karki A; Putra J; Kim SS; Laquaglia MJ; Perez-Atayde AR; Sadri-Vakili G; Vakili K
    Oncol Rep; 2019 Oct; 42(4):1487-1496. PubMed ID: 31322272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
    Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
    J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.
    Xiong S; Pant V; Zhang Y; Aryal NK; You MJ; Kusewitt D; Lozano G
    J Pathol; 2017 Mar; 241(4):501-510. PubMed ID: 27925213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
    Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
    Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
    Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
    Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM4 is a key therapeutic target in cutaneous melanoma.
    Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
    Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
    Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
    J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
    Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
    Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
    Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM4: What do we know about the association between its polymorphisms and cancer?
    Almeida GM; Castilho AC; Adamoski D; Braun-Prado K
    Med Oncol; 2022 Dec; 40(1):61. PubMed ID: 36566308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [mRNA levels detected by real-time quantitative RT-PCR in chronic lymphocytic leukemia and their clinical significance].
    Liu L; Fang C; Dong HJ; Wang DM; Zhu DX; Qiao C; Fan L; Miao KR; Liu P; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1145-9. PubMed ID: 22040960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long and the short of it: the MDM4 tail so far.
    Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
    J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
    Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.